Jeffrey Robinson, M.D.

  • Associate Professor of Medicine, Division of Pulmonary and Critical Care Medicine, School of Medicine
  • Director of Pulmonary Hypertension Program


Dr. Robinson was born and raised in Oregon and attended Albert Einstein College of Medicine. Following his internal medicine training at the University of California – Davis, he completed his pulmonary and critical care fellowship at University of Colorado, where he joined faculty as assistant professor. His academic interests include advancing the care of pulmonary hypertension through clinical trials. Clinically, his main interests are the care of patients with pulmonary hypertension and autoimmune-related lung disease. Additionally, Dr. Robinson attends in both the medical and cardiac intensive care units.

Education and training

    • M.D., 2008, University of California Davis
  • Internship

    • Internal Medicine, University of California Davis, Sacramento, California, 2009
  • Residency

    • Internal Medicine, University of California Davis, Sacramento, California, 2011
  • Fellowship

    • Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado, 2015

Memberships and associations:

  • American Thoracic Society
  • Pulmonary Hypertension Association
  • Pulmonary Vascular Research Institute

Areas of interest

  • Pulmonary arterial hypertension
  • Chronic thromboembolic pulmonary hypertension
  • Pulmonary embolism
  • Care of the critically ill
  • High altitude medicine

Honors and awards

  • Outstanding Teacher Award, Providence Internal Medicine, 2018
  • Awarded Medical Degree with Distinction in Cellular and Molecular Biology Research, 2008


Elsevier pure profile

Selected publications

  • Kumar R, Mickael C, Kassa B, Gebreab L, Robinson JC, Daniel Koyanagi D, Linda Sanders, Barthel L, Meadows C, Fox DL, Irwin D, Li M, B. Mckeown, Riddle SR, Brown RD, Morgan L, Evans C, Hernandez-Saavedra D, Bandeira A, Maloney J, Bull TM, Janssen W, Stenmark K, Tuder RM, Graham BB. TGF-β Activation by Bone Marrow-Derived Thrombospondin-1 Causes Schistosoma- and Hypoxia-Induced Pulmonary Hypertension. Nat Comm. 2017 May 30;8:15494. PMID: 28555642.
  • Robinson JC, Abbott C, Meadows CA, Roach RC, Honigman B, Bull TM.  Long-term health outcomes in high altitude pulmonary hypertension. High Alt Med and Bio. 2017 Mar;18(1):61-66. PMID: 28061144.
  • Tuder RM, Robinson JC, Graham BB.  Fatty acid metabolism, BMPR2 and the right ventricle.  Am J Resp Crit Care Med. 2016 Sept 15;194(6):655-6. PMID: 27628075.
  • Robinson JC, Pugliese SC, Fox DL, Badesch DB. Anticoagulation in Pulmonary Arterial Hypertension. Curr Hypertens Rep. 2016 Jun;18(6):47. PMID: 27137522.
  • Robinson JC, Graham BB, Rouault TC, Tuder RM.  The crossroads of iron with hypoxia and cellular metabolism: Implications in the pathobiology of pulmonary hypertension.  Am J Resp Cell and Mol Biol.  2014 Dec;51(6):751-729. PMID: 24988529
  • Tuder RM, Robinson JC, Graham BB.  Fat and cardiotoxicity in hereditary pulmonary hypertension.  Am J Resp Crit Care Med. 2014 Feb 1;189(3):247-9. PMID: 24484329.
  • Robinson JC, Tuder R, Hunt J.  Alpha-1 antitrypsin and the pathogenesis of emphysema.  Minerva Pneumologica.  2013 Dec; 52(4): 137-47.
  • Tuder RM, Stacher E, Robinson JC, Kumar R, Graham BB.  Pathology of pulmonary hypertension.  Clin Chest Med.  2013 Dec; 34: 639-650. PMID: 24267295.
  • Macht M, Robinson JC, Graham BB.  Updated approach for the assessment of ventilator associated pneumonia.  Crit Care Med.  2013 Nov; 41(11): 2641-2. PMID: 24162675.


  • {{[0].value }}